Cloud Banner

Pharmaceutical

Image

Global Prostate Cancer Therapeutics Market - Industry Trends and Forecast to 2029

  • Pharmaceutical
  • Upcoming Report
  • Feb 2022
  • Global
  • 350 Pages
  • No of Tables: 60
  • No of Figures: 220

Global Prostate Cancer Therapeutics Market, By Drug Class (Hormonal Therapy, Chemotherapy, Immunotherapy, Targeted Therapy), End-Users (Clinic, Hospital, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Sales,  Others), Country (U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa) Industry Trends and Forecast to 2029

Prostate Cancer Therapeutics Market

Market Analysis and Insights Global Prostate Cancer Therapeutics Market

Prostate cancer therapeutics market is expected to gain market growth in the forecast period of 2022-2029. Data Bridge Market Research analyses the market to account to grow at a CAGR of 8.2% in the above mentioned forecast period and is likely to reach the value USD 21.90 billion by 2029.

Prostate cancer is a kind of cancer in which abnormal cells in the prostate gland proliferate and expand uncontrollably. Prostate cancer is the sixth leading cause of death in males, and the eleventh leading cause of death from any disease. Radiation, chemotherapy, hormone therapy, surgery and biological therapy are all options for treating prostate cancer. Prostate cancer is treated and managed with a variety of diagnostic and therapeutic items, including prostatic adenocarcinoma, small cell carcinoma, benign prostatic hyperplasia, and others.

The rise in the number of cases of prostate cancer and cardiovascular disorders is the major driver resulting in the expansion of market’s growth. Another significant factor influencing the growth rate of prostate cancer therapeutics market is the rising healthcare expenditure. Furthermore, growing government funding and rising initiatives by public and private organisations to spread awareness about prostate cancer are the factors that will expand the prostate cancer therapeutics market. Other factors such as technical innovations linked with screening and diagnostic tests and changing lifestyle will positively impact the prostate cancer therapeutics market’s growth rate. Additionally, developments in genomics and proteomics and growing geriatric population will cushion the growth rate of prostate cancer therapeutics market. Emergence of strong pipeline drugs and presence of new prostate cancer treatments are the significant factors that will escalate the growth rate of prostate cancer therapeutics market.

Moreover, the rise in the research and development activities and innovative drugs will provide beneficial opportunities for the prostate cancer therapeutics market in the forecast period of 2022-2029. Also, high unmet needs and rise in the pharmaceutical expenditure by emerging markets will escalate the growth rate prostate cancer therapeutics market in future.

However, high cost associated with the treatment and less success rate in clinical trials for oncology drugs will impede the growth rate of prostate cancer therapeutics market. Additionally, adverse effects involved with prostate cancer therapeutics will hinder the prostate cancer therapeutics market growth. Less awareness and prolonged treatment durations will further challenge the market in the forecast period mentioned above.

This prostate cancer therapeutics market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the prostate cancer therapeutics market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Prostate Cancer Therapeutics Market Scope and Market Size

The prostate cancer therapeutics market is segmented on the basis of drug class, end-users and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

  • Based on drug class, prostate cancer therapeutics market is segmented into hormonal therapy, chemotherapy, immunotherapy and targeted therapy. Hormonal therapy has been further sub-segmented into luteinizing hormone-releasing hormone (LHRH) antagonists, luteinizing hormone-releasing hormone (LHRH) agonists and anti-androgen. Luteinizing hormone-releasing hormone (LHRH) antagonists have been divided into zytiga and gonax. Luteinizing hormone-releasing hormone (LHRH) agonists have been divided into lupron, zoladex, eligard, decapeptyl, vantas and others. Anti-Androgen has been divided into xtandi and casodex. Chemotheraphy has been further sub-segmented into taxotere and jevtana. Immunotheraphy has been further sub-segmented as provenge. Targeted therapy has been further sub-segmented as xofigo.
  • On the basis of end-users, the prostate cancer therapeutics market is segmented into clinic, hospital and others.
  • Prostate cancer therapeutics market has also been segmented on the basis of distribution channel into hospital pharmacies, retail pharmacies, online sales and others.

Prostate Cancer Therapeutics Market Country Level Analysis

Prostate cancer therapeutics market is analyzed and market size information is provided by the country, drug class, end-users and distribution channel as referenced above.

The countries covered in the prostate cancer therapeutics market report are the U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa.

North America dominates the prostate cancer therapeutics market due to the presence of major key players, high disposable income and well-developed healthcare infrastructure in this region. Asia-Pacific is expected to grow during the forecast period of 2022-2029 due to the increasing patient pool, rising investment in the healthcare sector, and growing government support.

The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Patient Epidemiology Analysis

Prostate cancer therapeutics market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

Competitive Landscape and Global Prostate Cancer Therapeutics Market Share Analysis

Prostate cancer therapeutics market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to prostate cancer therapeutics market research.

Some of the major players operating in the prostate cancer therapeutics market are Johnson & Johnson Private Limited, Astellas Pharma Inc., Ipsen Pharma, Sanofi, Bayer AG, AbbVie Inc., AstraZeneca, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Abbott, Takeda Pharmaceutical Company Limited., Bristol-Myers Squibb Company, GlaxoSmithKline plc, Novartis AG, F. Hoffmann-La Roche Ltd., Myovant Sciences GmbH, Tolmar Pharmaceuticals, Inc., Ferring B.V., Dendreon Pharmaceuticals LLC., and Genentech, Inc., among others.

Recent Development

  • In January 2021, U.S. Food and Drug Administration (FDA) have approved a new drug named Relugolix which is expected to modify the treatment for advanced prostate cancer. The medicine relugolix (Orgovyx) was found to be more successful at lowering testosterone levels in men with advanced prostate cancer in a substantial clinical trial.   
  • In June 2021, Novartis AG has announced that the U.S. Food and Drug Administration (FDA) have granted Breakthrough Therapy designation (BTD) to 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer (mCRPC). Breakthrough Therapy designation is given to drugs that are being studied for critical illnesses and show early clinical evidence of a significant improvement over current therapy.


SKU-

Please fill in the below form for detailed Table of Content

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Table

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Figure

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for Infographics

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Research Methodology:

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Please fill in the below form for Research Methodology

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Customization Available:

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Please fill in the below form for Available Customization

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

FREQUENTLY ASK QUESTIONS

The Prostate Cancer Therapeutics Market will be worth USD 21.90 billion in the forecast period by 2029.
The Prostate Cancer Therapeutics Market growth rate is 8.2% during the forecast period.
The rise in the number of cases of prostate cancer and cardiovascular disorders are the growth drivers of the Prostate Cancer Therapeutics Market.
The drug class, end-users and distribution channel are the factors on which the Prostate Cancer Therapeutics Market research is based.
Major companies in the Prostate Cancer Therapeutics Market are Johnson & Johnson Private Limited, Astellas Pharma Inc., Ipsen Pharma, Sanofi, Bayer AG, AbbVie Inc., AstraZeneca, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Abbott, Takeda Pharmaceutical Company Limited., Bristol-Myers Squibb Company, GlaxoSmithKline plc, Novartis AG, F. Hoffmann-La Roche Ltd., Myovant Sciences GmbH, Tolmar Pharmaceuticals, Inc., Ferring B.V., Dendreon Pharmaceuticals LLC., and Genentech, Inc.
Free Sample Report

CHOOSE LICENCE TYPE

  • 7000.00
  • 4800.00
  • 3000.00
  • 8000.00
  • 12000.00

Why Choose Us

Industry Coverage

DBMR works across the globe in multiple industries which equip us with knowledge across verticals and provide our clients with insights not only from their industry but how other industries will impact their ecosystem.

Regional Coverage

Coverage of Data Bridge is not restricted to developed or emerging economies. We work across the globe covering the largest array of countries where no other market research or business consulting firm has ever conducted research; creating growth opportunities for our clients in areas which are still unknown.

Technology Coverage

In today’s world, technology drives the market sentiment, so our vision is to provide our clients insights not only for developed technologies but upcoming and disrupting technological changes throughout the product lifecycle by enabling them with unforeseen opportunities in the market which will create disruption in their industry. This leads to innovation and our clients to come out as winners.

Goal Oriented Solutions

DBMR goal is to help our clients achieve their goals through our solutions; hence we formatively create the most appropriate solutions for our client needs, saving time and efforts for them to drive their grand strategies.

Unparallel Analyst Support

Our analysts take pride in our clients’ success. Unlike others, we believe in working along our clients to achieve their goals with 24 hours analyst support determining the correct needs and inspire innovation through service.

Banner

Client Testimonials